SIRT1 Activators Like Nicotinamide Riboside Prevent Neuron Damage in Mouse Model of Multiple Sclerosis: Preclinical Findings

Synopsis

Axonal damage and neuron loss contribute to permanent vision loss and neurological disability in optic neuritis and multiple sclerosis (MS). Current treatments mainly target inflammation but do little to protect neurons. In this study, researchers tested two SIRT1-activating drugs, nicotinamide riboside (SRT647) and SRT501, in a mouse model of MS. They found that intravitreal injection of these drugs significantly reduced retinal ganglion cell loss and preserved axon function, even though inflammation was not affected. The neuroprotective effects were dependent on SIRT1 activity, and a single dose of SRT501 was sufficient to limit neuron damage. These findings suggest that SIRT1 activators could be a promising therapy to prevent neuronal damage in optic neuritis and MS, potentially complementing existing immunomodulatory treatments.

Journal

Investigative Opthalmology & Visual Science